Watch the short on our channel — new research history breakdowns regularly. Research Use Only.
In the 1960s, workers on Brazilian plantations were collapsing after a single bite from the Bothrops jararaca pit viper — not from blood loss, but from blood pressure that crashed toward zero. That observation, followed carefully, ended in one of the most-prescribed drug classes on earth. This is the research-history version of the story. It is educational pharmacology, discussed strictly in a research-use-only context — nothing here is medical, dosing, or usage guidance.
The venom did one thing extraordinarily well
The jararaca's venom is rich in short peptides that were later named bradykinin-potentiating peptides (BPPs). Bradykinin is a signaling molecule the body uses to widen blood vessels; the venom peptides blocked the enzyme that normally breaks bradykinin down, so its blood-pressure-lowering effect ran unchecked. To the snake, this was a weapon. To a pharmacologist, it was a naturally occurring inhibitor of a specific human enzyme — a ready-made research tool.
Sérgio Ferreira asked the right question
Brazilian pharmacologist Sérgio Ferreira characterized the BPPs in the mid-1960s, and later work in Sir John Vane's laboratory connected them to their target: angiotensin-converting enzyme (ACE). ACE does two things that both raise blood pressure — it activates angiotensin II (a potent vasoconstrictor) and it degrades bradykinin (a vasodilator). A molecule that inhibits ACE therefore pushes blood pressure down from both directions. The venom had been doing exactly that all along.
From venom peptide to a pill
The first proof of concept was teprotide, a nine-amino-acid peptide taken directly from the venom. It worked — but only by injection, which made it impractical. The breakthrough came when chemists at Squibb, Miguel Ondetti and David Cushman, used the venom peptides as a structural starting point and engineered a small, orally active molecule that fit the same enzyme. The result was captopril, approved in 1981 as the first oral ACE inhibitor. Enalapril, lisinopril, ramipril and the rest of the class followed — all descendants of that same enzyme-inhibition idea first seen in venom.
Why this belongs in a peptide-research blog
Because the whole story is a peptide story. The active principle in the venom was a peptide; the first drug was a peptide; and the leap to a small molecule only happened after the peptides had mapped out exactly what the target enzyme wanted. It is a clean example of a recurring pattern in the literature: a peptide found in nature defines a mechanism, and the mechanism defines a class of research and, eventually, medicine. Understanding the peptide is what makes the rest legible.
The bottom line: a bite that emptied the blood pressure of grown men became the starting point for a drug class now found in medicine cabinets worldwide — and the bridge from one to the other was peptide chemistry. The public literature on all of this is extensive; this is a research and history overview, not advice.